After an up-and-down year, Nektar watches development head Wei Lin walk away as it pursues pipeline rebound

Nicole DeFeudis

Editor

More than any other year in recent memory, 2020 was a rollercoaster of highs and lows —mostly lows. Just ask San Francisco’s Nektar: Despite ditching …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

After an up-and-down year, Nektar watches development head Wei Lin walk away as it pursues pipeline rebound

Nicole DeFeudis

Editor

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Sofinnova outlines $550M fund after IPOs and M&A deals

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

GSK's Zejula-Jemperli combo in ovarian cancer hits primary endpoint, misses on overall survival

Af­ter an up-and-down year, Nek­tar watch­es de­vel­op­ment head Wei Lin walk away as it pur­sues pipeline re­bound

Nicole DeFeudis

Editor

Sign up to read this article for free.

more like this

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

GSK's Ze­ju­la-Jem­per­li com­bo in ovar­i­an can­cer hits pri­ma­ry end­point, miss­es on over­all sur­vival

After an up-and-down year, Nektar watches development head Wei Lin walk away as it pursues pipeline rebound

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Sofinnova outlines $550M fund after IPOs and M&A deals

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

GSK's Zejula-Jemperli combo in ovarian cancer hits primary endpoint, misses on overall survival